Claims
- 1. A compound of the formula ##STR114## or a pharmaceutically acceptable salt or geometrical or optical isomer thereof wherein:
- X is S;
- Y is O or S;
- Z is S;
- Alk is --CH.sub.2 --CH.sub.2 --CH.sub.2 --;
- R.sub.1 is hydrogen, methyl or ethyl;
- n is 1, 2, or 3; and
- R.sub.2 is lower alkyl or cycloalkyl.
- 2. A compound according to claim 1 wherein Y is O and R.sub.2 is methyl, ethyl, or cyclohexyl.
- 3. A compound according to claim 1 wherein Y is S and R.sub.2 is methyl or ethyl.
- 4. A compound, which is diethyl 4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropyl]thio]methyl]-1,3 -oxathiolane-2,2-dipropanoate and isomers thereof.
- 5. A compound, which is 4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]methyl]-1,3-oxathiolane-2,2-dipropanoic acid and isomers thereof.
- 6. A compound, which is 4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]methyl-2-methyl-1,3-oxathiolane-2-propanoic acid and isomers thereof.
- 7. A compound, according to claim 4, which is 4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]methyl]-2-ethyl-1,3-oxathiolane-2-butanoic acid and isomers thereof.
- 8. A compound, according to claim 1, which is 4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]methyl]-2-cyclohexyl-1,3-oxathiolane-2-butanoic acid and isomers thereof.
- 9. A compound, according to claim 1, which is 4-[[[3-(acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]methyl]-2-methyl-1,3-oxathiolane-2-acetic acid and isomers thereof.
- 10. A compound, according to claim 1, which is 4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]methyl]-2-ethyl-1,3-oxathiolane-2-propanoic acid and isomers thereof.
- 11. A compound, according to claim 1, which is (.+-.)trans-4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy) propyl]thio]methyl]-2-ethyl-1,3-oxathiolane-2-propanoic acid and isomers thereof.
- 12. A compound, according to claim 1, which is (.+-.)cis-4-[[[-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]methyl]-2-ethyl-1,3-oxathiolane-2-propanoic acid and isomers thereof.
- 13. A compound, according to claim 1, which is 4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio)methyl]-2-ethyl-1,3-dithiolane-2-butanoic acid and isomers thereof.
- 14. A compound, according to claim 1, which is 4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]ethyl]-2-methyl-1,3-dithiolane-2-acetic acid and isomers thereof.
- 15. A compound, according to claim 1, which is (.+-.)trans-4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]methyl]-2-ethyl-1,3-dithiolane-2-propanoic acid and isomers thereof.
- 16. A compound, according to claim 1, which is (.+-.)cis-4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio)methyl]-2-ethyl-1,3-dithiolane-2-propanoic acid and isomers thereof.
- 17. A compound according to claim 1 which is 4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]methyl]-2methyl-1,3-dithiolane-2-butanoic acid, sodium salt and isomers thereof.
- 18. A compound according to claim 1 which is 4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxypropyl]thio]methyl-2-methyl-1,3-dithiolane-2-butanoic acid, sodium salt and isomers thereof.
- 19. A compound according to claim 1 which is 4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]-thio]methyl]-2-ethyl-1,3-oxathiolane-2-propanoic acid, disodium salt and isomers thereof.
- 20. A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula ##STR115## or a pharmaceutically acceptable salt or geometrical or optical isomer thereof wherein:
- X, Y, and Z are each independently O or S with S optionally oxidized to S=O;
- Alk is straight or branched chain alkylene or hydroxyalkylene containing 1-6 carbon atoms;
- R.sub.1 is hydrogen or lower alkyl;
- n is 0 to 5;
- R.sub.2 is hydrogen, lower alkyl, cycloalkyl, --(CH.sub.2).sub.n --CO.sub.2 R.sub.1, phenyl, phenyl substituted with halo, lower alkyl or lower alkoxy; and
- Ar is 5,6,7,8-tetrahydro-1-naphthalenyl, phenyl, or phenyl substituted with lower alkyl, hydroxy, lower alkoxy, or lower alkanoyl; and a pharmaceutically acceptable carrier.
- 21. A pharmaceutical composition according to claim 20 comprising a therapeutically effective amount of a compound of the formula ##STR116## or a pharmaceutically acceptable salt or geometrical or optical isomer thereof wherein:
- X, Y, and Z are each independently O or S with S optionally oxidized to S=O;
- Alk is straight or branched chain alkylene or hydroxyalkylene containing 1-6 carbon atoms;
- R.sub.1 is hydrogen or lower alkyl;
- n is 0 to 5; and
- R.sub.2 is hydrogen, lower alkyl, cycloalkyl, --(CH.sub.2).sub.n --CO.sub.2 R.sub.1, phenyl, phenyl substituted with halo, lower alkyl or lower alkoxy;
- and a pharmaceutically acceptable carrier.
- 22. A pharmaceutical composition according to claim 20 comprising a therapeutically effective amount of a compound of the formula ##STR117## or a pharmaceutically acceptable salt or geometrical or optical isomer thereof wherein:
- X, Y, and Z are each independently O or S with S optionally oxidized to S.dbd.O;
- Alk is straight or branched chain alkylene or hydroxyalkylene containing 1-6 carbon atoms;
- R.sub.1 is hydrogen or lower alkyl;
- n is 0 to 5;
- R.sub.2 is hydrogen, lower alkyl, --(CH.sub.2).sub.n --CO.sub.2 R.sub.1, phenyl, phenyl substituted with halo, lower alkyl or lower alkoxy; and R.sub.3 is lower alkyl;
- and a pharmaceutically acceptable carrier.
- 23. A pharmaceutical composition according to claim 21 comprising a therapeutically effective amount of a compound of the formula ##STR118## or a pharmaceutically acceptable salt or geometrical or optical isomer thereof wherein:
- X is S;
- Y is O or S;
- Z is S;
- Alk is --CH.sub.2 --CH.sub.2 --CH.sub.2 --;
- R.sub.1 is hydrogen, methyl, or ethyl;
- n is 1, 2, or 3; and
- R.sub.2 is lower alkyl or cycloalkyl;
- and a pharmaceutically acceptable carrier.
- 24. A pharmaceutical composition according to claim 23 wherein Y is O and R.sub.2 is methyl, ethyl, or cyclohexyl.
- 25. A pharmaceutical composition according to claim 23 wherein Y is S and R.sub.2 is methyl or ethyl.
- 26. A pharmaceutical composition according to claim 21 wherein said compound is 4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy]thio]methyl-2-ethyl-1,3-oxathiolane-2-propanoic acid.
- 27. A pharmaceutical composition according to claim 21 wherein said compound is 4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio methyl]-2-ethyl-1,3-oxathiolane-2-propanoic acid, sodium salt.
- 28. A pharmaceutical composition according to claim 21 wherein said compound is 4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio methyl]-2-ethyl-1,3-oxathiolane-2-propanoic acid, disodium salt.
- 29. A pharmaceutical composition according to claim 21 wherein said compound is (.+-.)trans-4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]methyl]-2-ethyl-1,3-oxathiolane-2-propanoic acid.
- 30. A pharmaceutical composition according to claim 21 wherein said compound is (.+-.)cis-4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]methyl]-2-ethyl-1,3-oxathiolane-2-propanoic acid.
- 31. A method of treating allergy comprising administering to an animal in need of such treatment a therapeutically effective amount of a compound of the formula ##STR119## or a pharmaceutically acceptable salt or geometrical or optical isomer thereof wherein:
- X, Y, and Z are each independently O or S with S optionally oxidized to S=O;
- Alk is straight or branched chain alkylene or hydroxyalkylene containing 1-6 carbon atoms;
- R.sub.1 is hydrogen or lower alkyl;
- n is 0 to 5; and
- R.sub.2 is hydrogen, lower alkyl, cycloalkyl, --(CH.sub.2).sub.n --CO.sub.2 R.sub.1, phenyl, phenyl substituted with halo, lower alkyl or lower alkoxy.
- 32. A method according to claim 31 of treating allergy comprising administering to an animal in need of such treatment a therapeutically effective amount of compound of the formula ##STR120## or a pharmaceutically acceptable salt or geometrical or optical isomer thereof wherein:
- X is S;
- Y is O or S;
- Z is S;
- Alk is --CH.sub.2 --CH.sub.2 --CH.sub.2 --;
- R.sub.1 is hydrogen, methyl or ethyl;
- n is 1,2, or 3; and
- R.sub.2 is lower alkyl or cycloalkyl.
- 33. A method according to claim 32 wherein Y is O and R.sub.2 is methyl, ethyl, or cyclohexyl.
- 34. A method according to claim 32 wherein Y is S and R.sub.2 is methyl or ethyl.
- 35. A method of treating inflammatory diseases comprising administering to an animal in need of such treatment a therapeutically effective amount of compound of the formula ##STR121## or a pharmaceutically acceptable salt or geometrical or optical isomer thereof wherein:
- X, Y, and Z are each independently O or S with S optionally oxidized to S=O;
- Alk is straight or branched chain alkylene or hydroxyalkylene containing 1-6 carbon atoms;
- R.sub.1 is hydrogen or lower alkyl;
- n is 0 to 5;
- R.sub.2 is hydrogen, lower alkyl, --(CH.sub.2).sub.n --CO.sub.2 R.sub.1, phenyl, phenyl substituted with halo, lower alkyl or lower alkoxy; and R.sub.3 is lower alkyl.
- 36. A method according to claim 31 wherein said compound is 4-[[[3-(4-acetyl-3-hydroxy-2-propylphenyl)propyl]thio]methyl]-2-ethyl-1,3-oxathiolane-2-propanoic acid.
- 37. A method according to claim 31 wherein said compound is 4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]methyl]-2-ethyl-1,3-oxathiolane-2-propanoic acid, sodium salt.
- 38. A method according to claim 31 wherein said compound is 4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]methyl]-2-ethyl-1,3-oxathiolane-2-propanoic acid, disodium salt.
- 39. A method according to claim 31 wherein said compound is (.+-.)trans-4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]methyl]-2-ethyl-1,3-oxathiolane-2-propanoic acid.
- 40. A method according to claim 31 wherein said compound is (.+-.)cis-4-[[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]methyl]-2-ethyl-1,3-oxathiolane-2-propanoic acid.
Parent Case Info
This is a continuation-in-part of application Ser. No. 07/100,685 filed Sept. 24, 1987 now U.S. Pat. No. 4,808,729.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4710505 |
Robin et al. |
Dec 1987 |
|
Foreign Referenced Citations (3)
Number |
Date |
Country |
1448340 |
Jun 1966 |
FRX |
0004493 |
Oct 1966 |
FRX |
1445013 |
Oct 1966 |
FRX |
Non-Patent Literature Citations (1)
Entry |
McCarthy, et al., J. Med. Chem., 28:1145-1147, (1985). |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
100685 |
Sep 1987 |
|